Ollin Biosciences
Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD
$330MSeries B
Role not disclosedRC
RA Capital Management
Activity from announced rounds
Activity in this selectionJun 30, 2026 · Jun 1, 2026
RA Capital Management founds, funds and scales companies in healthcare and planetary health, combining scientific research with capital from seed through public-market financings.
Its TechAtlas research platform informs investment decisions through detailed scientific and market analysis. Raven, its healthcare incubator, works on originating and co-creating companies, giving researchers a route from a scientific idea to a funded business.
Blackbird provides a clinical development accelerator alongside the investment platform. These capabilities are relevant for founders who need to design a development programme and reach clinical milestones, as well as finance laboratory or commercial work.
Sources
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $456.5M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionNorthLinks Bio
Develops broad-spectrum antiviral prophylactic therapies for respiratory infections
$34MUndisclosed
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosed